This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Investor Alert: Holzer Holzer & Fistel, LLC Advises Investors Of Upcoming Deadlines In Shareholder Litigation Involving Delcath Systems, Inc., Amyris, Inc., Nam Tai Electronics, Inc. And Accretive Health, Inc.
Holzer Holzer & Fistel LLC reminds investors of upcoming deadlines for applications to serve as lead plaintiff in securities class action lawsuits against Delcath Systems, Inc. (DCTH), Amyris, Inc. (AMRS), Nam Tai Electronics, Inc. (NTE) and Accretive Health, Inc. (AH).
Investors that suffered significant losses investing in any of these companies during the specified times who are interested in potentially serving as lead plaintiff in the respective class actions are encouraged to contact Michael I. Fistel, Jr., Esq. (
firstname.lastname@example.org) or Marshall P. Dees, Esq. (
email@example.com) by email or via toll-free telephone at (888) 508-6832 to discuss their legal rights.
A lead plaintiff is a representative party appointed by the court to act on behalf of other class members in directing the litigation. Any member of the purported class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
Delcath Systems Inc.
A class action lawsuit has been filed on behalf of investors who purchased Delcath (NASDAQ: DCTH) common stock between April 21, 2010 and May 2, 2013, inclusive, alleging the company violated the federal securities laws by, among other things, misrepresenting the status of its New Drug Application for the commercial sale of its Melblez Kit.
The deadline to seek appointment as lead plaintiff in this lawsuit, which is pending in the United States District Court for the Eastern District of Pennsylvania, is July 8, 2013. More information about the lawsuit and the firm are available at
A class action lawsuit has been filed on behalf of investors who purchased Amyris, Inc. (NASDAQ: AMRS) common stock between April 29, 2011 and February 8, 2012. The lawsuit alleges the company violated the federal securities laws by issuing false and misleading statements regarding Amyris’s ability to commercially produce Biofene.